GLA Monotherapy for Use in Cancer Treatment

Abstract

The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.

What is claimed is: 
     
         1 . A method of treating a mammal who suffers from cancer, comprising administering an effective amount of a composition comprising GLA, said composition comprising:
 (a) GLA of the formula:   
       
         
           
           
               
               
           
         
         wherein: 
         R 1 , R 3 , R 5  and R 6  are C 11 -C 20  alkyl; and 
         R 2  and R 4  are C 12 -C 20  alkyl; and 
         (b) a pharmaceutically acceptable carrier or excipient; 
         wherein the composition does not comprise antigen. 
       
     
     
         2 . The method of  claim 1  wherein R 1 , R 3 , R 5  and R 6  are undecyl and R 2  and R 4  are tridecyl. 
     
     
         3 . The method of any of  claim 1  or  2  wherein the mammal is human. 
     
     
         4 . The method of any of  claims 1 - 3 , wherein the composition is an aqueous formulation. 
     
     
         5 . The method of any of  claims 1 - 3 , wherein the composition is in the form of an oil-in-water emulsion, a water-in-oil emulsion, liposome, micellar formulation, or a microparticle. 
     
     
         6 . The method of any of  claims 1 - 5 , wherein the cancer comprises a solid tumor. 
     
     
         7 . The method of  claim 6 , wherein the solid tumor is a carcinoma, a sarcoma or a lymphoma. 
     
     
         8 . The method of  claim 6 , wherein the solid tumor is a primary solid tumor. 
     
     
         9 . The method of  claim 6 , wherein the solid tumor is a secondary solid tumor. 
     
     
         10 . The method of any of  claims 1 - 5 , wherein the cancer is selected from the group consisting of, melanoma, Merkel cell carcinoma, lung cancer, cervical cancer, ovarian cancer, uterine cancer, breast cancer, liver cancer, gastric cancer, prostate cancer, colon cancer, kidney cancer, bladder cancer, brain cancer, and pancreatic cancer. 
     
     
         11 . The method of any of  claims 1 - 10 , wherein the composition is administered by subcutaneous, intradermal, intramuscular, intratumoral, or intravenous injection. 
     
     
         12 . The method of any of  claims 1 - 10 , wherein the composition is administered intranasally or intrapulmonary. 
     
     
         13 . The method of any of  claims 1 - 12 , wherein the composition is administered in conjunction with one or more additional therapeutic agents or treatments. 
     
     
         14 . The method of  claim 13 , wherein the therapeutic agents is an immune checkpoint inhibitor. 
     
     
         15 . The method of  claim 13 , wherein the therapeutic agent is an antibody that activates a co-stimulatory pathway. 
     
     
         16 . The method of  claim 15 , wherein the antibody is an anti-CD40 antibody. 
     
     
         17 . The method of  claim 13 , wherein the therapeutic agent is a cancer therapeutic agent. 
     
     
         18 . The method of  claim 17 , wherein the cancer therapeutic agent is selected from the group consisting of taxotere, carboplatin, trastuzumab, epirubicin, cyclophosphamide, cisplatin, docetaxel, doxorubicin, etoposide, 5-FU, gemcitabine, methotrexate, and paclitaxel, mitoxantrone, epothilone B, epidermal-growth factor receptor (EGFR)-targeting monoclonal antibody 7A7.27, vorinostat, romidepsin, docosahexaenoic acid, bortezomib, shikonin and an oncolytic virus. 
     
     
         19 . The method of  claim 13  wherein the one or more additional therapeutic treatments is radiation therapy.